TEL AVIV, Israel, May 13, 2019 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage investments in these companies by improving understanding of their industries and markets.
In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and TASE.
Summary of Highlights
Continues to strengthen its leading platform BL-8040; received FDA Orphan Drug Designation for BL-8040 (pancreatic cancer) and Biological Product Designation for AGI-134; successfully raised $15M; significant catalysts expected for H2-2019 (See full report).
The platform is currently being evaluated in eight Phase 2 or Phase 3 clinical trials for multiple indications in collaboration with four global pharma companies. So far BL-8040 is showing highly promising results in all three of its verticals, including more effective and less costly SCM for autologous transplantation, increased survival and response rates in AML consolidation patients, and increased survival and immunologic response in solid tumor patients.
BioLineRx is becoming a leader in the development of novel immune therapeutics for the treatment of cancer. The Company has enough cash to further support its clinical progress through the next 18-24 months.
Read the full report here.
Please remember that you can contact us to receive additional details and insights on our covered companies at no cost: email@example.com
About the company - BioLineRx Ltd. (hereinafter: "BioLineRx" or "the Company") is an Israeli clinical-stage biopharmaceutical company focused on oncology. Their two leading drug candidates under clinical development include: 1) BL-8040, a cancer therapy platform that is proving effective on 3 different verticals - stem cell mobilization (SCM); acute myeloid leukemia (AML); and solid tumors and 2) AGI-134, an immunotherapy treatment for multiple solid tumors. In 2007, the Company was listed on the Tel Aviv Stock Exchange and since 2011 has also been traded on the NASDAQ Capital Market.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
SOURCE Frost & Sullivan